ARCT Arcturus Therapeutics Holdings Inc.
USHealthcareAs of 2026-08-24
Why ARCT matters now
Arcturus Therapeutics Holdings Inc. (ARCT) is a US stock in Healthcare. The latest InvestLog snapshot shows $14.34 with +6.62% on the session and $407.6M in market capitalization; recent performance reads 1-month +12.56% and YTD +22.84%.
The latest financial table shown here is Q1 2026, with revenue of $610.0K, net income of $-27.0M, and EPS of $-0.95. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -27.5%.
The latest indexable market news headline is "Arcturus Therapeutics Eyes Phase III CF Call, OTC Data as Vaccine Funds Pipeline" from MarketBeat.
Additional event context on this page matters because analyst consensus is Buy with a median target of $22.50; recent insider activity includes Marantz Jing L. filing A-Award. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
1.12
P/S
4.72
EV/EBITDA
-0.39
DCF Value
$-5.70
FCF Yield
-27.5%
Div Yield
0.0%
Margins & Returns
Gross Margin
91.2%
Operating Margin
-196.7%
Net Margin
-173.5%
ROE
-36.6%
ROA
-32.1%
ROIC
-41.4%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $610.0K | $-27.0M | $-0.95 |
| Q4 2025 | $3.1M | $-29.1M | $-1.05 |
| FY 2025 | $67.2M | $-65.8M | $-2.40 |
| Q3 2025 | $17.2M | $-13.4M | $-0.49 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$22.50
Target (Median)
$22.50
Target Range
$20.00 - $25.00
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
—
Beta
2.35
Arcturus Therapeutics Holdings Inc. is a biotechnology company focused on RNA-based medicines, developing a pipeline of vaccines for infectious diseases alongside treatments for rare liver and respiratory conditions across the United States. Its notable development programs encompass LUNAR-OTC, designed for ornithine transcarbamylase (OTC) deficiency, and LUNAR-CF, targeting cystic fibrosis lung disease caused by specific CFTR gene mutations. The company also advances vaccine initiatives such as LUNAR-COV19 and LUNAR-FLU. Arcturus has cultivated a range of strategic collaborations, including partnerships with Vinbiocare Biotechnology Joint Stock Company for manufacturing COVID-19 vaccines; Janssen Pharmaceuticals, Inc., to create nucleic acid-based therapies for hepatitis B virus; Ultragenyx Pharmaceutical, Inc., for developing mRNA therapeutics aimed at rare disease targets; CureVac AG, to progress mRNA therapeutic and vaccine candidates across various indications; the Singapore Economic Development Board and Duke-NUS Medical School, specifically for the LUNAR-COV19 vaccine; and Millennium Pharmaceuticals, Inc., focused on discovering siRNA medicines for non-alcoholic steatohepatitis (NASH). Founded in 2013, Arcturus Therapeutics maintains its corporate headquarters in San Diego, California.